The charged particle transverse momentum (pT) spectra are presented for pp
collisions at sqrt(s)=0.9 and 7 TeV. The data samples were collected with the
CMS detector at the LHC and correspond to integrated luminosities of 231
inverse microbarns and 2.96 inverse picobarns, respectively. Calorimeter-based
high-transverse-energy triggers are employed to enhance the statistical reach
of the high-pT measurements. The results are compared with both leading-order
QCD and with an empirical scaling of measurements at different collision
energies using the scaling variable xT = 2 pT/sqrt(s) over the pT range up to
200 GeV/c. Using a combination of xT scaling and direct interpolation at fixed
pT, a reference transverse momentum spectrum at sqrt(s)=2.76 TeV is
constructed, which can be used for studying high-pT particle suppression in the
dense QCD medium produced in heavy-ion collisions at that centre-of-mass
energy.
Disciplines :
Education & instruction
Author, co-author :
Zhan, Y
Guo, J
Yang, W
Goncalves, C
Rzymski, T
Dreas, A
Zylkjewicz, E
Mikulski, M
Brzózka, K
Golas, A
Kong, Y
Ma, M
Huang, F
Huor, B
Guo, Q
Da Silva, SD
Torres, J
Cai, Y
Topisirovic, I
Su, J
Bijian, K
Alaoui-Jamali, MA
Huang, S
Journe, Fabrice ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Anatomie humaine et Oncologie expérimentale
Forman SB, et al. Is superficial spreading melanoma still the most common form of malignant melanoma? J Am Acad Dermatol. 2008;58(6):1013-1020.
Chan KK, Chan RC, Ho RS, Chan JY. Clinical patterns of melanoma in Asians: 11-year experience in a tertiary referral center. Ann Plast Surg. 2016;77(suppl 1):S6-S11.
Kong Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res. 2011;17(7):1684-1691.
Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
Carvajal RD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-2334.
Guo J, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-2909.
Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161(7):1681-1696.
Todd JR, Scurr LL, Becker TM, Kefford RF, Rizos H. The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene. 2014;33(2):236-245.
Todd JR, Becker TM, Kefford RF, Rizos H. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell Melanoma Res. 2013;26(4):518-526.
Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731-745.
Khosravi S, Tam KJ, Ardekani GS, Martinka M, McElwee KJ, Ong CJ. eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion. J Invest Dermatol. 2015;135(5):1358-1367.
Carter JH, et al. Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma. Br J Cancer. 2016;114(4):444-453.
Fukunaga R, Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 1997;16(8):1921-1933.
Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997;16(8):1909-1920.
Furic L, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A. 2010;107(32):14134-14139.
Ueda T, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A. 2010;107(32):13984-13990.
Robichaud N, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 2015;34(16):2032-2042.
Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 2004;64(23):8639-8642.
Wendel HG, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232-3237.
Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget. 2012;3(2):118-131.
Grzmil M, et al. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-? signaling pathway in human glioblastoma. Cancer Res. 2011;71(6):2392-2402.
Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther. 2009;8(15):1463-1469.
Wyman K, et al. Multicenter Phase II trial of highdose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005-2011.
Hodi FS, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-3190.
Woodman SE, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009;8(8):2079-2085.
Lyle M, Long GV. Diagnosis and treatment of KIT-mutant metastatic melanoma. J Clin Oncol. 2013;31(26):3176-3181.
Antonescu CR, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182-4190.
DiNitto JP, Wu JC. Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. Crit Rev Biochem Mol Biol. 2011;46(4):295-309.
Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2014;201:27-65.
Wang X, et al. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression. Oncotarget. 2016;7(7):8029-8042.
Hsieh AC, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55-61.
Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336.
Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D. Treatment with dasatinib for chronic myeloid leukemia following imatinibinduced hepatotoxicity. Int J Hematol. 2014;99(1):91-94.
Yang X, et al. Autophagy protects against dasatinibinduced hepatotoxicity via p38 signaling. Oncotarget. 2015;6(8):6203-6217.
Kong JH, et al. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol. 2007;118(4):205-208.
Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011;25(2):201-210.
Li P, et al. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget. 2016;7(35):56811-56825.
Bell JB, et al. MNK inhibition disrupts mesenchymal glioma stem cells and prolongs survival in a mouse model of glioblastoma. Mol Cancer Res. 2016;14(10):984-993.
Lock R, et al. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J Clin Invest. 2016;126(6):2181-2190.
Wheater MJ, Johnson PW, Blaydes JP. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther. 2010;10(7):728-735.
Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6(9):3614-3620.
Bales E, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res. 2005;65(3):692-697.
Kluger HM, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117(10):2202-2208.
Shoushtari AN, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354-3362.
Roux PP, Topisirovic I. Regulation of mRNA translation by signaling pathways. Cold Spring Harb Perspect Biol. 2012;4(11):a012252.
Feng Y, et al. SBI-0640756 attenuates the growth of clinically unresponsive melanomas by disrupting the eIF4F translation initiation complex. Cancer Res. 2015;75(24):5211-5218.
Zhan Y, et al. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. J Invest Dermatol. 2015;135(5):1368-1376.
Kosciuczuk EM, et al. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood. 2016;128(3):410-414.
Kosciuczuk EM, Saleiro D, Platanias LC. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia. Cytokine. 2017;89:116-121.
Gandin V, et al. Polysome fractionation and analysis of mammalian translatomes on a genomewide scale. J Vis Exp. 2014;(87):51455.